These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 30827260)
1. Harnessing Stem Cells and Neurotrophic Factors with Novel Technologies in the Treatment of Parkinson's Disease. Conese M; Cassano R; Gavini E; Trapani G; Rassu G; Sanna E; Di Gioia S; Trapani A Curr Stem Cell Res Ther; 2019; 14(7):549-569. PubMed ID: 30827260 [TBL] [Abstract][Full Text] [Related]
2. Insights into the Effects of Mesenchymal Stem Cell-Derived Secretome in Parkinson's Disease. d'Angelo M; Cimini A; Castelli V Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32718092 [TBL] [Abstract][Full Text] [Related]
3. Old and new challenges in Parkinson's disease therapeutics. Pires AO; Teixeira FG; Mendes-Pinheiro B; Serra SC; Sousa N; Salgado AJ Prog Neurobiol; 2017 Sep; 156():69-89. PubMed ID: 28457671 [TBL] [Abstract][Full Text] [Related]
4. Secretome released from hydrogel-embedded adipose mesenchymal stem cells protects against the Parkinson's disease related toxin 6-hydroxydopamine. Chierchia A; Chirico N; Boeri L; Raimondi I; Riva GA; Raimondi MT; Tunesi M; Giordano C; Forloni G; Albani D Eur J Pharm Biopharm; 2017 Dec; 121():113-120. PubMed ID: 28965958 [TBL] [Abstract][Full Text] [Related]
5. Human olfactory stem cells: As a promising source of dopaminergic neuron-like cells for treatment of Parkinson's disease. Alizadeh R; Kamrava SK; Bagher Z; Farhadi M; Falah M; Moradi F; Boroujeni ME; Soleimani M; Kamyab A; Komeili A Neurosci Lett; 2019 Mar; 696():52-59. PubMed ID: 30552942 [TBL] [Abstract][Full Text] [Related]
6. Can mesenchymal stem cells reduce vulnerability of dopaminergic neurons in the substantia nigra to oxidative insult in individuals at risk to Parkinson's disease? Datta I; Bhonde R Cell Biol Int; 2012 Jul; 36(7):617-24. PubMed ID: 22417707 [TBL] [Abstract][Full Text] [Related]
7. Clinical potential and current progress of mesenchymal stem cells for Parkinson's disease: a systematic review. Chen Y; Shen J; Ke K; Gu X Neurol Sci; 2020 May; 41(5):1051-1061. PubMed ID: 31919699 [TBL] [Abstract][Full Text] [Related]
8. Intranigral transplantation of epigenetically induced BDNF-secreting human mesenchymal stem cells: implications for cell-based therapies in Parkinson's disease. Somoza R; Juri C; Baes M; Wyneken U; Rubio FJ Biol Blood Marrow Transplant; 2010 Nov; 16(11):1530-40. PubMed ID: 20542127 [TBL] [Abstract][Full Text] [Related]
9. GDNF-secreting mesenchymal stem cells provide localized neuroprotection in an inflammation-driven rat model of Parkinson's disease. Hoban DB; Howard L; Dowd E Neuroscience; 2015 Sep; 303():402-11. PubMed ID: 26166730 [TBL] [Abstract][Full Text] [Related]
11. Current Research and Use of Mesenchymal Stem Cells in the Therapy of Autoimmune Diseases. Chen Y; Yu Q; Hu Y; Shi Y Curr Stem Cell Res Ther; 2019; 14(7):579-582. PubMed ID: 31729289 [TBL] [Abstract][Full Text] [Related]
12. Impact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson's Disease. Teixeira FG; Carvalho MM; Panchalingam KM; Rodrigues AJ; Mendes-Pinheiro B; Anjo S; Manadas B; Behie LA; Sousa N; Salgado AJ Stem Cells Transl Med; 2017 Feb; 6(2):634-646. PubMed ID: 28191785 [TBL] [Abstract][Full Text] [Related]
13. Dopaminergic differentiation of neural progenitors derived from placental mesenchymal stem cells in the brains of Parkinson's disease model rats and alleviation of asymmetric rotational behavior. Park S; Kim E; Koh SE; Maeng S; Lee WD; Lim J; Shim I; Lee YJ Brain Res; 2012 Jul; 1466():158-66. PubMed ID: 22634376 [TBL] [Abstract][Full Text] [Related]
14. Functional role of mesenchymal stem cells in the treatment of chronic neurodegenerative diseases. Lo Furno D; Mannino G; Giuffrida R J Cell Physiol; 2018 May; 233(5):3982-3999. PubMed ID: 28926091 [TBL] [Abstract][Full Text] [Related]
15. Olfactory mucosa stem cells: An available candidate for the treatment of the Parkinson's disease. Simorgh S; Alizadeh R; Eftekharzadeh M; Haramshahi SMA; Milan PB; Doshmanziari M; Ramezanpour F; Gholipourmalekabadi M; Seifi M; Moradi F J Cell Physiol; 2019 Dec; 234(12):23763-23773. PubMed ID: 31173364 [TBL] [Abstract][Full Text] [Related]
16. Dual Effects of Human Placenta-Derived Neural Cells on Neuroprotection and the Inhibition of Neuroinflammation in a Rodent Model of Parkinson's Disease. Kim HW; Lee HS; Kang JM; Bae SH; Kim C; Lee SH; Schwarz J; Kim GJ; Kim JS; Cha DH; Kim J; Chang SW; Lee TH; Moon J Cell Transplant; 2018 May; 27(5):814-830. PubMed ID: 29871515 [TBL] [Abstract][Full Text] [Related]
17. The prospective role of mesenchymal stem cells in Parkinson's disease. Tambe P; Undale V; Sanap A; Bhonde R; Mante N Parkinsonism Relat Disord; 2024 Oct; 127():107087. PubMed ID: 39142905 [TBL] [Abstract][Full Text] [Related]
18. Changes in the secretome of tri-dimensional spheroid-cultured human mesenchymal stem cells in vitro by interleukin-1 priming. Redondo-Castro E; Cunningham CJ; Miller J; Brown H; Allan SM; Pinteaux E Stem Cell Res Ther; 2018 Jan; 9(1):11. PubMed ID: 29343288 [TBL] [Abstract][Full Text] [Related]
19. Mesenchymal Stem Cells-derived Exosomes: A New Possible Therapeutic Strategy for Parkinson's Disease? Vilaça-Faria H; Salgado AJ; Teixeira FG Cells; 2019 Feb; 8(2):. PubMed ID: 30717429 [TBL] [Abstract][Full Text] [Related]
20. Human Wharton's jelly mesenchymal stem cells protect axotomized rat retinal ganglion cells via secretion of anti-inflammatory and neurotrophic factors. Millán-Rivero JE; Nadal-Nicolás FM; García-Bernal D; Sobrado-Calvo P; Blanquer M; Moraleda JM; Vidal-Sanz M; Agudo-Barriuso M Sci Rep; 2018 Nov; 8(1):16299. PubMed ID: 30389962 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]